MX2018016103A - Metodos para manejar los efectos adversos en poblaciones de pacientes que necesitan una transfusion. - Google Patents

Metodos para manejar los efectos adversos en poblaciones de pacientes que necesitan una transfusion.

Info

Publication number
MX2018016103A
MX2018016103A MX2018016103A MX2018016103A MX2018016103A MX 2018016103 A MX2018016103 A MX 2018016103A MX 2018016103 A MX2018016103 A MX 2018016103A MX 2018016103 A MX2018016103 A MX 2018016103A MX 2018016103 A MX2018016103 A MX 2018016103A
Authority
MX
Mexico
Prior art keywords
adverse events
methods
patient populations
requiring transfusion
transfusion
Prior art date
Application number
MX2018016103A
Other languages
English (en)
Inventor
Cordero Rafael
Keegan Philip
Yoshida Tatsuro
D''alessandro Angelo
Dunham Andrew
Original Assignee
New Health Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Health Sciences Inc filed Critical New Health Sciences Inc
Publication of MX2018016103A publication Critical patent/MX2018016103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0272—Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

Metodo para medicina transfusional para reducir los episodios adversos en poblaciones de pacientes que reciben transfusiones sobre la base de una fisiologia subyacente del paciente.
MX2018016103A 2016-06-23 2017-06-22 Metodos para manejar los efectos adversos en poblaciones de pacientes que necesitan una transfusion. MX2018016103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662354041P 2016-06-23 2016-06-23
PCT/US2017/038859 WO2017223377A1 (en) 2016-06-23 2017-06-22 Methods for managing adverse events in patient populations requiring transfusion

Publications (1)

Publication Number Publication Date
MX2018016103A true MX2018016103A (es) 2019-05-02

Family

ID=59337864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016103A MX2018016103A (es) 2016-06-23 2017-06-22 Metodos para manejar los efectos adversos en poblaciones de pacientes que necesitan una transfusion.

Country Status (10)

Country Link
US (3) US20190388467A1 (es)
EP (2) EP4321215A3 (es)
JP (2) JP7053508B2 (es)
CN (2) CN115429961A (es)
AU (2) AU2017281514B2 (es)
BR (1) BR112018076512A2 (es)
CA (1) CA3028435A1 (es)
IL (3) IL305115A (es)
MX (1) MX2018016103A (es)
WO (1) WO2017223377A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4321215A3 (en) * 2016-06-23 2024-04-17 Hemanext Inc. Methods for managing adverse events in patient populations requiring transfusion
CA3063445A1 (en) 2017-05-19 2018-11-22 New Health Sciences, Inc. Methods and treatment of trauma
WO2020102602A1 (en) * 2018-11-16 2020-05-22 New Health Sciences, Inc. Methods for managing adverse events in patients with inflammation
WO2024086834A1 (en) * 2022-10-20 2024-04-25 Hemanext Inc. Treatment of burn patients with hypoxic blood
WO2024086835A1 (en) * 2022-10-20 2024-04-25 Hemanext Inc. Treatment of blood transfusion-dependent patients with hematologic malignancies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447987B1 (en) 1978-09-09 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Prolonged storage of red blood cells
US4769318A (en) 1986-06-03 1988-09-06 Ube Industries, Ltd. Additive solution for blood preservation and activation
US4880786A (en) 1987-01-14 1989-11-14 Ube Industries, Ltd. Additive solution for blood preservation and activation
US5120659A (en) 1989-06-26 1992-06-09 Mine Safety Appliances Company Deuterated water test method
US5789152A (en) 1991-04-30 1998-08-04 Basil T. Hone Composition and method for detecting HIV with baculovirus derived vesicles
US5476764A (en) 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US5624794A (en) 1995-06-05 1997-04-29 The Regents Of The University Of California Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas
US6162396A (en) 1997-04-26 2000-12-19 The Regents Of The University Of California Blood storage device and method for oxygen removal
US5789151A (en) 1997-05-15 1998-08-04 The Regents Of The University Of California Prolonged cold storage of red blood cells by oxygen removal and additive usage
US20020159995A1 (en) * 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US6413713B1 (en) 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
JP4564260B2 (ja) 2001-11-16 2010-10-20 ヒーマネクスト・エルエルシー 血液保存のための添加溶液
EP2187957A4 (en) * 2007-08-31 2011-08-24 Univ Michigan SELECTIVE CYTOPHERESIS DEVICES AND CORRESPONDING METHODS
US8430831B2 (en) * 2009-02-25 2013-04-30 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
WO2010147621A1 (en) * 2009-06-16 2010-12-23 The Trustees Of Columbia University In The City Of New York Methods for ameliorating adverse effects associated with transfusion of aged red blood cells
US9199016B2 (en) * 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
NZ622456A (en) * 2009-10-12 2015-09-25 New Health Sciences Inc Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
US8758286B2 (en) * 2009-12-01 2014-06-24 Exthera Medical Corporation Method for removing cytokines from blood with surface immobilized polysaccharides
EP2729000B1 (en) * 2011-07-05 2022-12-14 Hemanext Inc. A method for extended storage of red blood cells
US11013771B2 (en) * 2015-05-18 2021-05-25 Hemanext Inc. Methods for the storage of whole blood, and compositions thereof
EP4321215A3 (en) * 2016-06-23 2024-04-17 Hemanext Inc. Methods for managing adverse events in patient populations requiring transfusion

Also Published As

Publication number Publication date
IL297507B2 (en) 2024-01-01
JP2019521998A (ja) 2019-08-08
IL263695A (en) 2019-02-28
WO2017223377A1 (en) 2017-12-28
JP7053508B2 (ja) 2022-04-12
EP3474922A1 (en) 2019-05-01
IL263695B2 (en) 2023-03-01
JP2022093350A (ja) 2022-06-23
AU2017281514A1 (en) 2019-01-17
AU2022259846A1 (en) 2022-12-08
IL297507A (en) 2022-12-01
EP4321215A3 (en) 2024-04-17
US11090331B2 (en) 2021-08-17
IL297507B1 (en) 2023-09-01
US20230047634A1 (en) 2023-02-16
IL305115A (en) 2023-10-01
EP4321215A2 (en) 2024-02-14
AU2017281514B2 (en) 2022-11-24
CN109414542B (zh) 2022-09-09
CA3028435A1 (en) 2017-12-28
JP7267482B2 (ja) 2023-05-01
IL263695B (en) 2022-11-01
CN109414542A (zh) 2019-03-01
US20190388467A1 (en) 2019-12-26
BR112018076512A2 (pt) 2019-04-02
CN115429961A (zh) 2022-12-06
US20200276234A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
MX2018016103A (es) Metodos para manejar los efectos adversos en poblaciones de pacientes que necesitan una transfusion.
EP3511033A4 (en) SYSTEM FOR MANAGING INFORMATION REGARDING DIFFERENCES BETWEEN PERSONS IN DIALYSIS TREATMENT
BR112015017272A2 (pt) sistemas, métodos e aparelho de seleção de entrada agrícola
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2021008755A (es) Un anticuerpo anti-tau para usarse al tratar una tauopatia.
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
WO2014210077A3 (en) Systems and methods for establishing and updating clinical care pathways
MX2022005655A (es) Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l).
TW201613975A (en) Methods for treating multiple myeloma
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
SA517390475B1 (ar) نظام أكياس متعددة وطريقة لتحضير مكونات الدم
GB201309785D0 (en) Methods and systems for providing real-time information regarding objects in a network
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
PH12020550185A1 (en) Semaglutide in medical therapy
MA39599A (fr) Dosage et administration d'agents thérapeutiques anti-egfr
GB2540076A (en) Medical data management system
MX2017000118A (es) Biocontrol de enfermedades asociadas a la semilla en plantulas.
MX2017012449A (es) Tratamiento del dolor.
TW201614516A (en) Heterogeneous storing server and file storing method thereof
WO2014187964A3 (en) Novel treatment of metabolic diseases
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
UA84302U (ru) Способ коррекции иммунного статуса у больных рекуррентным депрессивным расстройством
UA92326U (ru) Способ коррекции системы антиоксидантной защиты у больных вегетативной дистонией с артериальной гипертензией
UA104585U (uk) Спосіб лікування гострого ішемічного інсульту
UA98639U (ru) Способ коррекции иммунного статуса у больных генерализованным тревожным расстройством